[Efficacy of adjuvant chemotherapy after left pneumonectomy on non-small cell lung cancer].
OBJECTIVE
Presently, whether non-small cell lung cancer (NSCLC) patients may benefit from adjuvant chemotherapy after left pneumonectomy is controversial. This study was to evaluate the efficacy of adjuvant chemotherapy after left pneumonectomy on NSCLC, and explore candidate patient selection for adjuvant chemotherapy.


METHODS
Clinical data of 51 NSCLC patients received radical left pneumonectomy and adjuvant chemotherapy of TP/NP regimen and 102 patients received left pneumonectomy alone between Jan. 1997 and Jan. 2002 were compared.


RESULTS
The 1-, 3-, and 5-year survival rates were 88.2%, 54.9%, and 36.1% in adjuvant chemotherapy group, and 76.5%, 37.3%, and 23.9% in control group (P>0.05). For the patients at stage N2 or IIIA, the 1-, 3-, and 5-year survival rates were significantly higher in adjuvant chemotherapy group than in control group (P<0.05). For the patients with preoperative forced expiratory volume at the first second (FEV1) of >2 L, the 1-, 3-, and 5-year survival rates were significantly higher in adjuvant chemotherapy group than in control group (P<0.05). For the patients aged of >65 or < o r =65, there was no significant difference in survival between the two groups (P>0.05).


CONCLUSIONS
For the NSCLC patients at stage IIIA, N2 or with preoperative FEV1 of >2 L, adjuvant chemotherapy after left pneumonectomy may improve survival rate. For the patients with good pulmonary function, even aged patients, adjuvant chemotherapy is needed.
Wang
Meng
M
Department of Thoracic Surgery, Tumor Hospital, Tianjin Medical University, Tianjin, 300060, PR China.
Wang
Chang-Li
CL
Gong
Li-Qun
LQ
Gu
Feng
F
Su
Yan-Jun
YJ
You
Jian
J
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D005260:Female; D005500:Follow-Up Studies; D005541:Forced Expiratory Volume; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage; D011013:Pneumonectomy; D015996:Survival Rate; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077235:Vinorelbine
D014747:Vinblastine; D016190:Carboplatin; D017239:Paclitaxel; D000077235:Vinorelbine